02126.HK
JW (Cayman) Therapeutics Co. Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 1.94
−3.72%Margins
Gross margin
45.8%
EBITDA margin
-96.8%
EBIT margin
-30.6%
Net margin
-205.2%
FCF margin
-16.9%
-210.3%
Return on equity
-114.2%
Return on assets
-20.0%
Return on invested capital
0.51x
Asset turnover
-HKD 89.6M
Cash from operations
HKD 1.10
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026